Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | CCR9 | P51686 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343308 | 0.77 | CCR9 (0.55) | KMT2AHDAC1HDAC6CCR9TDP1 | |
| SCHEMBL3320901 | 0.76 | MAPT (0.51) | KMT2ARAB9ATDP1NPC1L3MBTL1 | |
| SCHEMBL342775 | 0.74 | NOS2 (0.46) | CCR9RAB9ANPC1L3MBTL1 | |
| SCHEMBL29957277 | 0.70 | KEAP1 (0.50) | KMT2ATDP1MEN1 | |
| SCHEMBL6950315 | 0.70 | KEAP1 (0.50) | KMT2ATDP1MEN1 | |
| SCHEMBL13706438 | 0.70 | HDAC1 (0.55) | KMT2AHDAC1HDAC6RAB9ATDP1 | |
| SCHEMBL15136337 | 0.70 | HDAC1 (0.55) | KMT2AHDAC1HDAC6RAB9ANPC1 | |
| SCHEMBL4717993 | 0.69 | MEN1 (0.46) | KMT2ARAB9ATDP1NPC1MEN1 | |
| Hydrochloric Acid SCHEMBL9672401 | 0.69 | HDAC1 (0.53) | KMT2AHDAC1HDAC6KDM4E | |
| Hydrochloric Acid SCHEMBL3231047 | 0.69 | HDAC1 (0.53) | KMT2AHDAC1HDAC6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10364240-B2 | Aryl sulfonamides | ChemoCentryx. Inc. (US) | 2019-07-30 | — | — | US | disclosed |
| US-9890148-B2 | Aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20170369483-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20150080351-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130267492-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120014997-A1 | ARYL SULFONAMIDES | UNGASHE SOLOMON (US) | 2012-01-19 | — | — | US | disclosed |
| US-20090163498-A1 | Aryl Sulfonamides | CHEMOCENTRYX, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7420055-B2 | Antagonists of the chemokine receptor 9 (CCR9); inhibit TECK ligand; antiinflammatory agents and immunoregulators; inflammatory bowel disease; (2-phenylsulfonamidophenyl)-pyridinyl-methanones; N-[4-chloro-2(pyridine4-carbonyl)-phenyl]4-morpholin-4-yl-benzenesulfonamide | CHEMOCENTRYX, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-10364240-B2 | Aryl sulfonamides | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-20120014997-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-20170369483-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-20150080351-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-20090163498-A1 | Aryl Sulfonamides | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
| US-20130267492-A1 | ARYL SULFONAMIDES | CCR9, CCR1, CCR2 | EPHX2 574/4885KMT2A 2760/4885HDAC1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.